<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32481">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683824</url>
  </required_header>
  <id_info>
    <org_study_id>PANC0020</org_study_id>
    <secondary_id>NCI-2015-01887</secondary_id>
    <secondary_id>4593</secondary_id>
    <secondary_id>PANC0020</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02683824</nct_id>
  </id_info>
  <brief_title>Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers</brief_title>
  <official_title>Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjiv Sam Gambhir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 positron
      emission tomography (PET)/computed tomography (CT) in measuring response in patients with
      pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta
      [18F]-R01-MG-F2, are a family of membrane receptors that are overexpressed and attaches to
      various proteins which sense and respond to contact events that occur at the cell surface
      and may improve early detection of pancreatic cancer and improve patient selection for
      anti-integrin alpha-v-beta 6 therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the biodistribution and safety of [18F]FP-R01-MG-F2 in healthy volunteers.

      II. Evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with
      pancreatic cancer.

      OUTLINE:

      Patients receive [18F]FP-R01-MG-F2 intravenously (IV) and undergo PET/CT scan immediately
      after and at 60 and 120 minutes.

      After completion of study, patients are followed up at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)</measure>
    <time_frame>Up to 3 hours after tracer injection</time_frame>
    <description>From the Region-of-Interest (ROI) image analysis, the biodistribution data will be reported in percent injected dose per gram of tissue (%ID/g). ROI analysis will be performed on normal brain, thyroid, lungs, mediastinum, liver, spleen, intestines, kidneys, urinary bladder and gluteal muscle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution of [18F]FP-R01-MG-F2 (SUV)</measure>
    <time_frame>Up to 3 hours after tracer injection</time_frame>
    <description>From the Region-of-Interest (ROI) image analysis, the biodistribution data will be reported in Standardized Uptake Values (SUV). ROI analysis will be performed on normal brain, thyroid, lungs, mediastinum, liver, spleen, intestines, kidneys, urinary bladder and gluteal muscle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry of [18F]FP-R01-MG-F2 (rem/mCi)</measure>
    <time_frame>Up to 3 hours after tracer injection</time_frame>
    <description>Using the biodistribution data (uptake in %ID/g or SUV), the tracer's complete dosimetry across all organs, tissues or cells will be determined using the OLINDA software. These data will be reported in rem/mCi.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)</measure>
    <time_frame>Up to 3 hours after tracer injection</time_frame>
    <description>Using the biodistribution data (uptake in %ID/g or SUV), the tracer's complete dosimetry across all organs, tissues or cells will be determined using the OLINDA software. These data will be reported in mSv/MBq.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy Subject</condition>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT scan immediately after and at 60 and 120 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT scan immediately after and at 60 and 120 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo [18F] FP-R01-MG-F2 PET/CT scan</description>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_label>healthy patients</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_label>healthy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo [18F] FP-R01-MG-F2 PET/CT scan</description>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_label>healthy patients</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FP-R01-MG-F2</intervention_name>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_label>healthy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]-FDG</intervention_name>
    <arm_group_label>pancreatic cancer patients</arm_group_label>
    <arm_group_label>healthy patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HEALTHY VOLUNTEER INCLUSION CRITERIA:

               -  Must have no known medical problems and have had a full medical exam within 6
                  months of the study

               -  Must understand and voluntarily have signed an Informed Consent after its
                  contents have been fully explained

          -  PANCREATIC CANCER PATIENT INCLUSION CRITERIA:

               -  Provides written informed consent

               -  Diagnosed with pancreatic cancer and scheduled to undergo surgery

               -  Able to remain still for duration of each imaging procedure (about one hour)

        Exclusion Criteria:

          -  HEALTHY VOLUNTEER EXCLUSION CRITERIA:

               -  Pregnant or nursing

          -  PANCREATIC CANCER PATIENT EXCLUSION CRITERIA:

               -  Participant is pregnant or breast-feeding

               -  Patients with contraindications for PET/CT or who cannot complete a PET/CT scan

               -  Patients not able to comply with the study procedures

               -  Patients with serious uncontrolled concurrent medical illness that would limit
                  compliance with study requirements

               -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Gambhir</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krithika Rupnarayan</last_name>
      <phone>650-736-0959</phone>
      <email>krupnara@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Gambhir</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrei Iagaru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>January 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sanjiv Sam Gambhir</investigator_full_name>
    <investigator_title>Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research and Professor, by courtesy, of Bioengineering and of Materials Science and Engineering</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
